TIGIT Antagonist Monoclonal Antibody
- TIGIT (T-cell Immunoreceptor with Ig and ITIM domains) is a co-inhibitory receptor expressed on all T-cell subtypes, including regulatory T cells (Tregs), and NK cells. Expression of the TIGIT ligand on tumor cells therefore prevents immune cells from recognizing and attacking the tumor. Administration of TIGIT antagonistic antibodies prevents cancer-mediated immune suppression and provides a therapeutic benefit in several mouse models of cancer, both as a monotherapy and in combination with other checkpoint modulators.
- This anti-tumoral effect is increased with ADCC-enabling TIGIT antibody.
- EOS884448, iTeos’s clinical candidate antibody, will enter a Phase I clinical trial in the second half of 2019.